ClinicalTrials.gg
CompletedNCT00980018MACS0999Updated Jul 1, 2021Results posted

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment

A Phase 4 interventional study of Nilotinib in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
34th of 66
52 · median 55
Started
2009
with 7 others
Phase 4
12 of 66
1 open now
Registered
17th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 34th largest by enrollment, is one of 8 that started in 2009, is one of 12 in phase 4, and was the 17th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The purpose of this exploratory study will be to examine changes in chronic low grade chronic adverse events, measured by Common Terminology Criteria for Adverse Events (CTCAE) grading, when patients are switched from imatinib to nilotinib therapy.

03

Conditions studied

  • Chronic Myelogenous Leukemia

Keywords

  • CML
  • Leukemia
  • Tasigna
  • nilotinib
  • AMN107
  • CML-CP
  • Chronic Phase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 years of age
  2. (ECOG) 0, 1, or 2
  3. Diagnosis of CML-CP associated with Bcr-Abl quantifiable by RQ-PCR (IS)
  4. Patients must be an imatinib responder and achieved the following efficacy milestones as appropriate for the length of time on imatinib therapy as per protocol
  5. CML-CP patients initiated on any dose of imatinib
  6. Ability to provide written prior to any study related screening procedures being done

Exclusion criteria

Exclusion Criteria:

  1. Loss of CHR or cytogenetic response
  2. Prior accelerated phase or blast phase CML
  3. Previously documented T315I mutation
  4. Presence of chromosomal abnormalities (trisomy 8) and/or clonal evolution other than Ph+.
  5. Previous treatment with any other tyrosine kinase inhibitor except for imatinib.
  6. Treatment with other agents within 30 days of Day 1.
  7. History of non-compliance to medical regimens or inability to grant consent.
  8. Women who are pregnant, breast feeding, or of without a negative serum test at baseline. Male or female patients of childbearing potential unwilling to use precautions throughout the trial and 3 months following discontinuation of study drug. women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Women of childbearing potential must have a negative serum pregnancy test prior to the first dose of nilotinib.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    nilotinib

    Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).

    Drug: Nilotinib

Interventions

  • Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).

    Also known as: Tasigna, nilotinib, AMN107,

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Improvement in Imatinib Related Chronic Low Grade Non Hematologic Adverse Event (AE) After Switch to Treatment With Nilotinib at End of Cycle 3

    A patient was considered improved if 50% or more of the chronic imatinib-related chronic low grade nonhematologic AEs showed improvement (a decrease in CTCAE \[Common Terminology Criteria for Adverse Events\] grade or complete resolution).

    Time frame: End of Cycles 1, 2, and 3

Secondary outcomes

  1. Percentage of Participants Achieving Complete Cytogenetic Response (CCyR) After Switching to Nilotinib for Participants Not Reporting CCyR at Baseline

    Time to complete cytogenetic response is defined as time from baseline to first time of CCyR as documented by bone marrow cytogenetics. Cytogenetic response was assessed as applicable by bone marrow cytogenetics 6, 12, and 18 months after starting imatinib therapy. Assess CCyR by bone marrow cytogenics

    Time frame: Cycles 1, 2, 6, 9, and 12

  2. Percentage of Participants Achieving Major Molecular Response (MMR) After the Switch in the Therapy for Participants Not Reporting MMR at Baseline

    Major Molecular Response (MMR) value at Molecular MD is designated a percentage, which is equivalent to a 3-log reduction from a standardized baseline value from the International Randomized Interferon versus STI571 (IRIS) study or 0.1% per International Scale (IS). Time to MMR is defined as time from baseline to first time of MMR as documented by RQ-PCR

    Time frame: Cycles 1,2,3,6,9,12

  3. Log Change in BCR-Abl Transcript Level From Baseline After the Switch Therapy

    Levels of BCR-ABL transcripts were determined by quantitative RQ-PCR testing of peripheral blood and analyzed at a central testing laboratory. Log reduction in BCR-ABL transcripts levels from the standardized baseline value will be calculated for each sample from the reported percent ratio of BCR-ABL transcripts versus control gene transcripts converted to a reference standard.

    Time frame: Cycles 1,2,3,6,9, and 12

  4. Duration of Complete Cytogenetic Response

    Duration of Complete Cytogenetic Response is defined as the time from first CCyR to first loss of CCyR as documented by bone marrow cytogenetics, or by FISH assay, whichever is earlier. The duration of CCyR begins on the day of enrollment for patients reporting CCyR at baseline.

    Time frame: 18 months of follow up from the first documented response

  5. Time to Complete Cytogenetic Response in Participants Not Reporting at Baseline

    For time to CCyR, an event is defined as achievement of CCyR documented by bone marrow cytogenetics.

    Time frame: Cycle 12

  6. Duration of Major Molecular Response

    Duration of Major Molecular Response is defined as the time from first MMR to first loss of MMR as documented by RQ-PCR. The duration of MMR begins on the day of enrollment for patients reporting MMR at baseline.

    Time frame: 18 months of follow up from the first documented response

  7. Time to Major Molecular Response (MMR) in Participants With MMR Absent at Baseline

    For time to MMR, an event is defined as achievement of MMR documented by RQ-PCR. Patients with MMR at the Screening RQ-PCR assay are counted as having time to MMR equal to 0.

    Time frame: Cycles 1,2,3,6,9,12

  8. Time to Optimal Imatinib-related Adverse Event Improvement

    Time to optimal improvement is defined as the time when the sum of the total CTCAE toxicity grades for a patient's chronic low-grade imatinib-related adverse events reaches its minimum value.

    Time frame: 18 months of follow up from the date of the first dose of study drug to the time to maximum decrease in CTCAE grade of these events

07

Results

Posted Jul 1, 2021

Participant flow

The study was conducted at 15 centers in US and 4 centers in Canada from 10-December-2009 (first patient first visit) to 27-December-2012 (last patient last visit).

Participant flow — Overall Study
MilestoneNilotinib
Started52
Completed40
Not completed12
Withdrew: Adverse event8
Withdrew: Patient withdrew consent3
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants With Improvement in Imatinib Related Chronic Low Grade Non Hematologic Adverse Event (AE) After Switch to Treatment With Nilotinib at End of Cycle 3

A patient was considered improved if 50% or more of the chronic imatinib-related chronic low grade nonhematologic AEs showed improvement (a decrease in CTCAE \[Common Terminology Criteria for Adverse Events\] grade or complete resolution).

Time frame:
End of Cycles 1, 2, and 3
Reported as:
Count of participants · Participants
Percentage of Participants With Improvement in Imatinib Related Chronic Low Grade Non Hematologic Adverse Event (AE) After Switch to Treatment With Nilotinib at End of Cycle 3
ParticipantsNilotinib
End of Cycle 137
End of Cycle 243
End of Cycle 344
SecondaryPercentage of Participants Achieving Complete Cytogenetic Response (CCyR) After Switching to Nilotinib for Participants Not Reporting CCyR at Baseline

Time to complete cytogenetic response is defined as time from baseline to first time of CCyR as documented by bone marrow cytogenetics. Cytogenetic response was assessed as applicable by bone marrow cytogenetics 6, 12, and 18 months after starting imatinib therapy. Assess CCyR by bone marrow cytogenics

Time frame:
Cycles 1, 2, 6, 9, and 12
Reported as:
Count of participants · Participants
Percentage of Participants Achieving Complete Cytogenetic Response (CCyR) After Switching to Nilotinib for Participants Not Reporting CCyR at Baseline
ParticipantsNilotinib
Cycle 12
Cycle 23
Cycle 30
Cycle 62
Cycle 90
Cycle 120
SecondaryPercentage of Participants Achieving Major Molecular Response (MMR) After the Switch in the Therapy for Participants Not Reporting MMR at Baseline

Major Molecular Response (MMR) value at Molecular MD is designated a percentage, which is equivalent to a 3-log reduction from a standardized baseline value from the International Randomized Interferon versus STI571 (IRIS) study or 0.1% per International Scale (IS). Time to MMR is defined as time from baseline to first time of MMR as documented by RQ-PCR

Time frame:
Cycles 1,2,3,6,9,12
Reported as:
Count of participants · Participants
Percentage of Participants Achieving Major Molecular Response (MMR) After the Switch in the Therapy for Participants Not Reporting MMR at Baseline
ParticipantsNilotinib
Cycle 12
Cycle 26
Cycle 33
Cycle 62
Cycle 92
Cycle 120
SecondaryLog Change in BCR-Abl Transcript Level From Baseline After the Switch Therapy

Levels of BCR-ABL transcripts were determined by quantitative RQ-PCR testing of peripheral blood and analyzed at a central testing laboratory. Log reduction in BCR-ABL transcripts levels from the standardized baseline value will be calculated for each sample from the reported percent ratio of BCR-ABL transcripts versus control gene transcripts converted to a reference standard.

Time frame:
Cycles 1,2,3,6,9, and 12
Reported as:
Mean · log change from Baseline
Log Change in BCR-Abl Transcript Level From Baseline After the Switch Therapy
log change from BaselineNilotinib
Cycle 1-0.177 ± 0.3665
Cycle 2-0.407 ± 0.5748
Cycle 3-0.540 ± 0.6960
Cycle 6-0.718 ± 0.9313
Cycle 9-0.844 ± 0.9130
Cycle 12-0.902 ± 0.9913
SecondaryDuration of Complete Cytogenetic Response

Duration of Complete Cytogenetic Response is defined as the time from first CCyR to first loss of CCyR as documented by bone marrow cytogenetics, or by FISH assay, whichever is earlier. The duration of CCyR begins on the day of enrollment for patients reporting CCyR at baseline.

Time frame:
18 months of follow up from the first documented response
Reported as:
Mean · days
Duration of Complete Cytogenetic Response
daysNilotinib
Participants with CCyR at baseline319.7 ± 143.03
Participants achieving CCyR on study266.3 ± 86.73
SecondaryTime to Complete Cytogenetic Response in Participants Not Reporting at Baseline

For time to CCyR, an event is defined as achievement of CCyR documented by bone marrow cytogenetics.

Time frame:
Cycle 12
Reported as:
Median · months
Time to Complete Cytogenetic Response in Participants Not Reporting at Baseline
monthsNilotinib
Time to Complete Cytogenetic Response in Participants Not Reporting at Baseline1.9 (0.9 to 5.7)
SecondaryDuration of Major Molecular Response

Duration of Major Molecular Response is defined as the time from first MMR to first loss of MMR as documented by RQ-PCR. The duration of MMR begins on the day of enrollment for patients reporting MMR at baseline.

Time frame:
18 months of follow up from the first documented response
Reported as:
Mean · days
Duration of Major Molecular Response
daysNilotinib
Participants with MMR at baseline277.6 ± 166.88
Participants achieving MMR on study208.3 ± 123.61
SecondaryTime to Major Molecular Response (MMR) in Participants With MMR Absent at Baseline

For time to MMR, an event is defined as achievement of MMR documented by RQ-PCR. Patients with MMR at the Screening RQ-PCR assay are counted as having time to MMR equal to 0.

Time frame:
Cycles 1,2,3,6,9,12
Reported as:
Median · months
Time to Major Molecular Response (MMR) in Participants With MMR Absent at Baseline
monthsNilotinib
Time to Major Molecular Response (MMR) in Participants With MMR Absent at Baseline2.8 (1.8 to 5.8)
SecondaryTime to Optimal Imatinib-related Adverse Event Improvement

Time to optimal improvement is defined as the time when the sum of the total CTCAE toxicity grades for a patient's chronic low-grade imatinib-related adverse events reaches its minimum value.

Time frame:
18 months of follow up from the date of the first dose of study drug to the time to maximum decrease in CTCAE grade of these events
Reported as:
Median · months
Time to Optimal Imatinib-related Adverse Event Improvement
monthsNilotinib
Time to Optimal Imatinib-related Adverse Event Improvement1.9 (1.0 to 2.1)

Adverse events

Collected over 18 months of follow up from the date of the first dose of study drug to the time to maximum decrease in CTCAE grade of these events. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib0/52 (0%)9/52 (17.3%)49/52 (94.2%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventNilotinib
Cardiac arrestCardiac disorders1/52
Coronary artery diseaseCardiac disorders1/52
PancreatitisGastrointestinal disorders1/52
Pancreatitis acuteGastrointestinal disorders1/52
PainGeneral disorders1/52
Cholecystitis acuteHepatobiliary disorders1/52
BronchitisInfections and infestations1/52
GastroenteritisInfections and infestations1/52
Vulval cellulitisInfections and infestations1/52
Wound infection bacterialInfections and infestations1/52
Most frequent other events
Showing 10 of 40
Most frequent other events
EventNilotinib
FatigueGeneral disorders17/52
HeadacheNervous system disorders17/52
RashSkin and subcutaneous tissue disorders17/52
ConstipationGastrointestinal disorders14/52
ArthralgiaMusculoskeletal and connective tissue disorders12/52
PruritusSkin and subcutaneous tissue disorders12/52
NauseaGastrointestinal disorders11/52
DyspnoeaRespiratory, thoracic and mediastinal disorders9/52
Abdominal painGastrointestinal disorders8/52
DiarrhoeaGastrointestinal disorders8/52

Baseline characteristics

Safety Set : All participants who received at least one dose of study drug and had at least one post-baseline safety assessment.

Age, Continuous
Age, Continuous(years)Nilotinib
Mean51.7 ± 10.76
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female26
Male26
08

Study locations

23 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Hematology Oncology Services of Arkansas SC
    Little Rock, Arkansas 72205, United States
  • USC Norris Cancer Center LAC & USC Medical Center
    Los Angeles, California 90033, United States
  • Southwest Cancer Care Murrieta
    Poway, California 92064, United States
  • Rocky Mountain Cancer Centers RMCC - Aurora
    Greenwood Village, Colorado, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34655, United States
  • Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4
    Ocoee, Florida *see dep*, United States
  • Stroger Cook County Hospital John H. Stroger Hospital
    Chicago, Illinois 60612, United States
  • St. Francis Hospital and Health Centers IndianaBlood&MarrowTransplantn
    Beech Grove, Indiana 46107, United States
  • St. Agnes Hospital
    Baltimore, Maryland 21229, United States
  • St. Louis University Cancer Center
    Saint Louis, Missouri 63110, United States
  • Northwest Cancer Specialists Salmon Creek Office
    Portland, Oregon 97210, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • The Jones Clinic
    Germantown, Tennessee 38138, United States
  • Texas Oncology, P.A.
    Bedford, Texas 76022, United States
  • Presbyterian Hospital of Dallas TexasOncology@PresbyterianHosp
    Dallas, Texas 75231, United States
  • Texas Oncology Texas Oncology - Sugar Land
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center/University of Texas
    Houston, Texas 77031, United States
  • Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio(2)
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    Brampton, Ontario L6R 3J7, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3A 1A1, Canada
09

References and documents

Publications

  • Cortes JE, Lipton JH, Miller CB, Busque L, Akard LP, Pinilla-Ibarz J, Keir C, Warsi G, Lin FP, Mauro MJ. Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):286-96. doi: 10.1016/j.clml.2016.02.002. Epub 2016 Feb 16. PubMed 26993758 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2021, 8 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2009
First posted
Sep 18, 2009
Start
Dec 2009
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Jul 1, 2021
Last update
Jul 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00980018
Responsible party
Sponsor
First posted
Sep 18, 2009
Start date
Dec 2009
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Jul 1, 2021
Last update
Jul 1, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion